LQDA
Liquidia Corporation
NASDAQ · USHealthcareBiotechnology
$77.08-3.58%
Price as of Jul 20, 2026
LQDA growth
Liquidia Corporation growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +1936.7%
- EBITDA
- +148.4%
- EBIT
- +135.6%
- EPS
- +115.2%
- Free cash flow
- +138.3%
- Operating cash flow
- +148.4%
Forward estimates
- Revenue
- +10.8%
- EBITDA
- —
- EPS
- +656.4%
Three-year CAGR
- Revenue
- +115.0%
- EBITDA
- +62.6%
- EBIT
- +57.6%
- Net income
- +47.1%
- EPS
- +51.8%
- Free cash flow
- +59.3%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.